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Neovascularization is a critical requirement for tumour growth.
The development of new blood vessels in tumours depends on the
balance between stimulatory and inhibitory angiogenic factors
released from the tumour cells or cells inhabiting the tumour
microenvironment. Vascular endothelial growth factor (VEGF)
has been implicated in driving the process of angiogenesis in a
variety of tumours, including colon carcinoma (Takahashi et al,
1995). This factor, also known as vascular permeability factor or
vasculotropin, was initially described as a protein that increases
vascular permeability (Dvorak et al, 1979a, 1979b). Vascular
permeability factor was later found to be identical to VEGF, an
endothelial cell mitogen (Tischer et al, 1991). VEGF induces
angiogenesis in numerous in vitro and in vivo assays (Dvorak et al,
1979a; Ellis et al, 1996). The biological activity of VEGF seems to
be limited to endothelial cells. VEGF does not induce mitogenesis
in nonendothelial cells (with rare exceptions), and antibodies to
VEGF do not inhibit the growth of tumour cells in vitro (Kim et al,
1993).
VEGF is expressed in nearly all cell types, but many malignant
tumour cells overexpress VEGF. Studies from our laboratory and
others suggest that VEGF expression is intimately associated with
inducing and maintaining the neovasculature of human colon
cancers (Takahashi et al, 1995, 1997; Warren et al, 1995; Ellis et
al, 1996, 1998). Although VEGF has received considerable study
recently, the factors that regulate its production in colon cancer
have not been fully elucidated. Hypoxia is one factor that has
been shown to up-regulate VEGF in numerous tumour systems
(Shweiki et al, 1995; Ellis et al, 1998). However, other factors
are important in the up-regulation of VEGF expression (Rak et al,
1995; Gille et al, 1997; Ellis et al, 1998). VEGF is induced by
several factors, and this ubiquitous sensitivity suggests that it plays
an important role in the survival and growth of a tumour. In
previous studies, we investigated the role of cytokines and growth
factors indigenous to sites of colon cancer growth on VEGF induc-
tion. We initially found that insulin-like growth factor-I (IGF-I)
and interleukin-1b (IL-1b) strongly induced VEGF expression in
human colon cancer cells (Akagi et al, 1998). This previous report
focused solely on the IGF-I induction of VEGF. In the present
study, we further examine the role of IL-1b in inducing VEGF and
the mechanism by which this occurs.
MATERIALS AND METHODS
Materials
Recombinant human IL-1b was purchased from R & D Systems,
Inc. (Minneapolis, MN, USA). Dactinomycin (ActD) was
purchased from Calbiochem-Novabiochem Corporation (La Jolla,
CA, USA).
Cell lines and culture conditions
The human colon cancer cell lines HT29 and SW620 were
obtained from the American Type Culture Collection (Rockville,
MD, USA). These cells were cultured and maintained in minimal
essential medium (MEM) supplemented with 10% fetal bovine
serum (FBS), 2 U ml–1 penicillin–streptomycin, vitamins, 1 mM
sodium pyruvate, 2 mML -glutamine and non-essential amino acids
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at 37°C in 5% carbon dioxide and 95% air. All experiments were
performed after the cells were grown to 90–95% confluence to
avoid the effects of cell density on VEGF expression (Koura et al,
1996).
IL-1b treatment of cells and time course of VEGF
induction
To determine the time course of IL-1b induction of VEGF, HT29
cells were incubated in 5% serum-containing medium overnight
and were then incubated in the presence or absence of IL-1b
(10 ng ml–1) for 1, 2, 4, 8, 24, or 48 h in serum-free medium. Total
RNA was extracted from the cells as described below. VEGF
mRNA expression was determined by Northern blot analysis. The
supernatant of each sample was collected and centrifuged to
remove debris, and stored at –70°C until assayed for protein level.
We also examined the effect of IL-1b on VEGF expression in
SW620 colon cancer cells to assure that the effect of IL-1b on
VEGF induction was not due to a phenomenon unique to the HT29
cell line. The time at which VEGF expression peaked was used in
subsequent studies.
IL-1b dose–response of VEGF induction
To determine the dose–response of IL-1b induction of VEGF,
HT29 cells were incubated in 5% serum-containing medium
overnight and then in serum-free medium containing 0.1, 1, 5, 10,
or 20 ng ml–1 of IL-1-b for 24 h. Total RNA was extracted from the
cells and Northern blots were done. Cells incubated in serum-free
medium without IL-1b were used as controls at each time point.
The supernatant of each sample was collected, centrifuged to
remove debris and stored at –70°C.
mRNA extraction and Northern blot analysis
Total RNA was extracted from cells by using Tri Reagent
(Molecular Research Center, Inc., Cincinnati, OH, USA).
Northern blot hybridization was performed as described pre-
viously (Koura et al, 1996). Briefly, total RNA (25 mg) was sepa-
rated by electrophoresis in 1% denaturing formaldehyde-agarose
gels. The RNA was transferred to the Hybond-N+ positively
charged nylon membrane (Amersham Life Science, Arlington
Heights, IL, USA) overnight by capillary elution and UV cross-
linked at 120 000 mJ cm–2 with a UV Stratalinker 1800
(Stratagene, La Jolla, CA, USA). After the blots were pre-
hybridized for 3–4 h at 65°C in rapid hybridization buffer
(Amersham), the membranes were hybridized overnight at 65°C
with the cDNA probe for VEGF or glyceraldehyde 3-phosphate
dehydrogenase (GADPH). The probed nylon membranes were
then washed and exposed to radiographic film.
cDNA probes
The cDNA probes used in this analysis were a human VEGF-
specific 204-base-pair probe, a gift of Brygida Berse (Harvard
Medical School, Boston, MA, USA) (Berse et al, 1992), and a
GAPDH probe, purchased from the American Type Culture
Collection. The VEGF probe identifies all alternatively spliced
forms of its mRNA transcripts. Probes were purified by agarose
gel electrophoresis by using the QIAEX Gel Extraction kit
(QIAGEN, Inc., Chatworth, CA, USA). Each cDNA probe was
radiolabelled with [a-32P] deoxyribonucleotide triphosphate by the
random-priming technique with the Rediprime labelling system
(Amersham).
Determination of VEGF protein levels
The total protein concentration was quantified spectrophotometri-
cally. The VEGF protein level in the supernatant was determined
with an enzyme-linked immunosorbent assay (ELISA) kit
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN, USA).
VEGF promoter-reporter studies in response to IL-1b
The role of transcriptional regulation of VEGF by IL-1b was
examined by using transient transfection techniques to examine
the activity of the VEGF promoter-luciferase reporter construct.
The following plasmids were used: pGL3-VEGF (containing the
human VEGF promoter linked to the firefly luciferase reporter
gene), pRLTK (an internal control plasmid containing the herpes
simplex thymidine kinase promoter linked to a constitutively
active Renilla luciferase reporter gene), and pGL3 (plasmid
vector alone as a negative control) (Akagi et al, 1998). HT29 cells
(5 ´ 106) were seeded and grown to 60–70% confluence. pRLTK
and pGL3-VEGF (5 mg:20 mg) were co-transfected into cells by
using the LipoFectin method (Life Science, Grand Island, NY,
USA) as outlined by the manufacturers. pRLTK and pGL3 were
co-transfected as a negative control. After cells were incubated in
the transfection medium for 20 h, the medium was changed to
standard medium and incubated for another 12 h. Cells were then
incubated in the presence or absence of IL-1b or cobalt chloride
(CoCl2) (200 mM) for 24 h (the period determined to afford the
greatest induction of VEGF mRNA). Cells were harvested with
passive lysis buffer (Dual-Luciferase Reporter Assay System;
Promega, Madison, WI, USA), and luciferase activity was
determined with a single sample luminometer as outlined in the
manufacturer’s protocol. CoCl2 was used as a positive control
because of its ability to mimic the hypoxic response (Minchenko
et al, 1994).
Effect of IL-1b on VEGF transcriptional activity
To confirm that the increase in VEGF mRNA in colon cancer cells
was due to an increase in transcription, transcriptional activity was
blocked with ActD before the cells were treated with IL-1b. HT29
cells, incubated in 5% serum MEM overnight, were incubated in
the presence or absence of ActD (1 mg ml–1) 2 h before their expo-
sure to IL-1b (optimal dosing to avoid cell death was determined
in preliminary experiments) in serum-free medium. Total RNA
was extracted from the cells after 24 h, and Northern blot analysis
was done. Control cells were treated with ActD without IL-1b.
VEGF mRNA half-life after induction by IL-1b
To determine the effect of IL-1b on VEGF mRNA stability, HT29
cells were incubated in the presence or absence of IL-1b for 24 h.
Further transcription in cells was then blocked by the addition of
ActD (final concentration of 1 mg ml–1). Total RNA was extracted
from the cells 0, 0.25, 0.5, 1, 2 and 4 h after the addition of ActD,
and Northern blot analysis was done for VEGF mRNA expression.
VEGF mRNA expression at each time point was compared to the1508 Y Akagi et al
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control value (total RNA extracted from cells before ActD treat-
ment was arbitrarily defined as 100%). The half-life of VEGF
mRNA was determined by plotting relative VEGF mRNA expres-
sion levels on a semilogarithmic axis versus time (Cricket
Software, Malvern, PA, USA).
Densitometric quantification
The software program Image Quant (Molecular Dynamics,
Sunnyvale, CA, USA) was used to quantify the VEGF mRNA
expression and GAPDH mRNA transcripts in the linear range of
the film. GAPDH mRNA was used as an internal control for
loading. Statistical analysis was done using InStat software for
Macintosh (GraphPad Software, San Diego, CA, USA).
RESULTS
Time course of IL-1b induction of VEGF mRNA and
protein in human colon cancer cells
VEGF mRNA expression in HT29 cells had increased more than
five times the baseline level at 24 h after treatment with IL-1b
(Figure 1). However, control cells that were grown in serum-free
medium without the addition of IL-1b also exhibited an increase in
VEGF mRNA expression, which was most pronounced at 48 h.
We have observed this effect before, when we demonstrated that
serum starvation increases VEGF mRNA between 24 and 48 h
after incubation in serum-free medium (Akagi et al, 1998).
Therefore, after densitometric analysis, we corrected for the
increase in VEGF expression due to serum starvation by
subtracting it from the increase in VEGF mRNA expression in the
cells treated with IL-1b (Akagi et al, 1998). In SW620 cells, the
peak induction of VEGF by IL-1b also occurred at 24 h, and the
extent of the increase was similar to that of HT29 cells (data not
shown).
To determine whether the increase in VEGF mRNA expression
induced by IL-1b was associated with an increase in VEGF
protein, we measured VEGF protein levels in the supernatants by
ELISA (Figure 1B). In cells treated with IL-1b, VEGF protein
levels increased 80% in the supernatants compared to control cells.
Dose–response of VEGF mRNA and protein secretion
induced by IL-1b in HT29 cells
We also determined the dose–response relationship of VEGF
induction by IL-b by incubating HT29 cells in increasing concen-
trations of IL-1b for 24 h. The increase in VEGF expression at
doses ranging from 1 ng ml–1 to 20 ng ml–1 followed a plateau
pattern (Figure 2A). VEGF protein levels also increased at doses
greater than 1 ng ml–1, but not so much as the mRNA (Figure 2B).
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Figure 1 Time course of IL-1b induction of VEGF in human colon cancer cells. (A) HT29 cells were treated with IL-1b in serum-free medium for the indicated
times, total RNA was extracted, and Northern blot analyses was done for expression of VEGF mRNA. A representative Northern blot is shown in the upper
panel. For each time point, untreated cells were used as a control as previously described (Akagi, 1998 #408). GAPDH mRNA transcripts were used as an
internal control to correct for loading differences. In the lower panel, a bar graph depicts relative increases in VEGF expression by densitometric analysis in
experiments repeated for each time point. On average, IL-1b induced a greater than fourfold increase in VEGF mRNA expression in HT29 cells at 24 h.
*Denotes significant difference from untreated cells at each time point by unpaired Student’s t-test. (B) VEGF protein level was measured in the conditioned
medium by ELISA 24 h after treatment with IL-1b. VEGF protein secreted from cells treated with IL-1b was 80% greater than the control
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IL-1b increased VEGF mRNA expression by an increase
in transcriptional activity
To determine the mechanism by which IL-1b induces VEGF,
transient transfections were done with VEGF promoter-reporter
constructs in HT29 cells. Control cells transfected with pGL3
(plasmid vector alone) and pRLTK demonstrated no increase in
promoter activity (Figure 3A). Cells transfected with pGL3-VEGF
(promoter-reporter construct) and pRLTK and treated with CoCl2
(positive control) demonstrated a more than 500% increase in
activity. Cells transfected with pGL3-VEGF and pRLTK and
treated with IL-1b similarly demonstrated an almost 300%
increase in activity.
To determine that the mechanism by which IL-1b induced
VEGF mRNA expression occurred at a transcriptional level, tran-
scription in HT29 cells was blocked with ActD before the addition
of IL-1b. This transcription blockade completely inhibited the
induction of VEGF mRNA expression (Figure 3B). These results
suggest that IL-1b induction of VEGF is regulated by an increase
in transcription of the gene.
IL-1b did not alter the stability of VEGF mRNA
To further explore the mechanism by which IL-1b enhanced the
expression of VEGF mRNA, we investigated the stability of
VEGF mRNA by examining its half-life. The half-life of VEGF
mRNA treated with IL-1b was similar to that of cells not exposed
to IL-1b, demonstrating that the half-life of VEGF mRNA was not
prolonged by treatment with IL-1b (Figure 4).
DISCUSSION
Several laboratories have demonstrated that the degree of neovas-
cularization in primary colon cancer specimens correlates with
tumour aggressiveness (Frank et al, 1995; Takahashi et al, 1995,
1997). Previous studies from our laboratory have demonstrated an
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Figure 3 Induction of VEGF transcription by IL-1b. (A) HT29 cells were co-transfected with pGL3-VEGF (VEGF promoter-luciferase reporter construct) and
pRLTK (to control for transfection efficiency), with the negative control being transfection with pGL3 and pRLTK. Twenty-four hours after transient transfection,
cells were treated with IL-1b (10 ng ml–1), CoCl2 (200 mM; positive control), or serum-free medium (negative control) for 24 h. Luciferase activity was determined,
and relative promoter activity was displayed graphically. IL-1b increased the activity of the VEGF promoter constructs ~ threefold. (B) HT29 cells were treated
with ActD (1 mg ml–1) for 2 h to block further transcription, after which cells were treated with IL-1b for 24 h, and RNA was extracted and northern blots were
done. Cells treated with IL-1b but not ActD were used as a positive control. Pretreatment with ActD blocked IL-1b induction of VEGF mRNA
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association between VEGF expression and vessel count in colon
cancer (Takahashi et al, 1995, 1997). Other studies have also
demonstrated the importance of VEGF in the growth and metas-
tasis of human colon cancer; for example, giving neutralizing
VEGF antibodies to mice bearing human colon cancer xenografts
decreases tumour growth and inhibits metastasis (Warren et al,
1995). Thus VEGF seems to be an important factor in determining
the angiogenic phenotype in human colon cancers.
In experimental tumour models, increased expression of VEGF
has been associated with increased tumour growth. Transfection of
VEGF into a breast carcinoma cell line increased in vivo tumour
growth and vessel density (Zhang et al, 1995). In a similar study,
overexpression of VEGF by a melanoma cell line increased
tumour growth, angiogenesis and experimental metastasis (Claffey
et al, 1996). In another study, the growth and vascularity of a rat
glioma cell line in nude mice decreased after transfection with an
antisense VEGF construct (Saleh et al, 1996).
Neutralizing antibodies to VEGF decrease tumour growth in
mice bearing tumours that express VEGF (e.g. glioblastoma, rhab-
domyosarcoma and leiomyosarcoma) (Kim et al, 1993). Tumour
cell proliferation in vitro was not affected by the antibodies,
suggesting that the decrease in tumour growth in vivo was due to
the VEGF antibodies’ anti-angiogenic effect. More recently, anti-
bodies to VEGF decreased tumour growth in vivo in an experi-
mental model of liver metastasis from colon cancer (Warren et al,
1995).
VEGF participates in numerous physiologic processes and has
been detected in nearly all cells in the body. Therefore, factors that
up-regulate its expression may contribute to angiogenesis and a
more aggressive tumour phenotype. Hypoxia, the best-character-
ized mediator of VEGF induction, increases VEGF expression
within 3–6 h; subsequent normalization of oxygen tension causes
VEGF mRNA to return to baseline levels (Ikeda et al, 1995).
Hypoxic induction of VEGF may be regulated by an increase in
the transcription or stabilization of the mRNA (Ikeda et al, 1995;
Levy et al, 1995, 1996). However, hypoxia is but one of a large
number of factors that induce VEGF expression. Several cytokines
and growth factors are known to affect VEGF expression as well.
Factors shown to increase VEGF expression in tumour cells
include tumour necrosis factor, transforming growth factor-a,
epidermal growth factor, IGF-I and PDGF-BB (Akagi et al, 1998;
Tsai et al, 1995; Ryuto et al, 1996). However, not all of these
factors increase VEGF expression in all tumour systems, i.e. the
factors involved in the regulation of VEGF may depend on the
tumour system under study. In addition, it is not clear whether
these factors affect common signal transduction pathways or
multiple pathways in the regulation of VEGF expression.
IL-1b is known to stimulate the proliferation of vascular smooth
muscle cells and is involved in modifying a number of vascular
functions by inducing autocrine production of chemotactic
cytokines on endothelial cells, including IL-1b itself (Libby et al,
1988; Mantovani and Dejana, 1989; Mantovani et al, 1992).
Moreover, IL-1b has been shown to enhance the production of
IL-8 protein, which has been shown to induce angiogenesis in
melanoma cells (Koch et al, 1992; Strieter et al, 1992; Gutman
et al, 1995). These observations suggest that IL-1b may alter the
functional properties of vascular cells, including the induction of
angiogenesis. Vascular-biology studies have shown that IL-1b
increase VEGF mRNA in rat aortic smooth muscle cells in a time-
and dose-dependent manner (Li et al, 1995). This induction of
VEGF expression was found to be due to an increase in transcrip-
tion as well as an increase in the stability of its mRNA. However,
the role of IL-1b on the induction of VEGF in tumours, specifi-
cally human colon cancer, is undefined.
We have demonstrated that IL-1b induced VEGF mRNA
expression in two human colon cancer cell lines. VEGF mRNA
induction by IL-1b peaked at 24 h, and no demonstrable
dose–response was found above an initial threshold concentration.
The increase in VEGF expression was due to an increase in
transcription of the VEGF gene, as shown by two separate
investigative strategies. However, the half-life of VEGF mRNA
induced by IL-1b was not prolonged. The induction of VEGF tran-
scription by IL-1b treatment is consistent with findings in other
cell lines (Li et al, 1995). The observation that the mRNA half-life
was not prolonged is consistent with the effect of other cytokines
and growth factors on VEGF induction (Akagi et al, 1998). Others
also have shown that IL-1b induces expression of another member
of the VEGF family, VEGF-C, in lung fibroblasts by an increase in
transcription alone (Ristimaki et al, 1998).
Little is known about the transcription factors that are activated
by treatment with IL-1b. IL-1b has been shown to mediate the
transcriptional activation of IL-2 through AP-1 sites, and the
5¢  flanking region of the VEGF gene contains several AP-1
binding sites (Muegge et al, 1989; Tischer et al, 1991). It is
therefore possible that IL-1b increases VEGF transcription by
activating pathways that lead to AP-1 activation and binding to
the VEGF promoter.
IL-1b is an inflammatory cytokine present in activated immune
cells. Solid tumours, including colon cancer, are infiltrated by
numerous immune effector cells, including macrophages and
lymphocytes, through the expression of platelet-derived endothe-
lial cell growth factor (Takahashi et al, 1996). This infiltration of
immune effector cells occurs in both primary and metastatic
cancer. We have shown elsewhere that infiltrating cells may
contribute to the angiogenesis of human colon cancer (Takahashi
et al, 1996). IL-1b induction of VEGF in human colon cancer cells
could be another mechanism by which infiltrating cells contribute
to tumour angiogenesis.
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Figure 4 Effect of IL-1b on VEGF mRNA half-life. HT29 cells were
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